1. HIV-1 self-testing to improve the efficiency of pre-exposure prophylaxis delivery: a randomized trial in Kenya.
- Author
-
Ortblad, Katrina F., Kearney, John E., Mugwanya, Kenneth, Irungu, Elizabeth M., Haberer, Jessica E., Barnabas, Ruanne V., Donnell, Deborah, Mugo, Nelly Rwamba, Baeten, Jared M., and Ngure, Kenneth
- Subjects
- *
PRE-exposure prophylaxis , *HIV prevention , *TEST design , *BLOOD sampling , *DIAGNOSIS of HIV infections , *HIV infection transmission , *CLINICAL trials , *HIV , *HIV infections , *PREVENTIVE health services , *RISK assessment , *SALIVA , *HEALTH self-care , *SERODIAGNOSIS , *TIME , *VIRAL antibodies , *TREATMENT effectiveness , *PREDICTIVE tests , *ANTI-HIV agents , *SEXUAL partners - Abstract
Background: The introduction of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus-1 (HIV-1) prevention in Africa presents new challenges for health systems that are already overburdened because PrEP delivery requires frequent clinic visits (generally every 3 months) for HIV-1 testing and PrEP refills. HIV-1 self-testing (HIVST) has the potential to improve the efficiency of PrEP delivery by decreasing the number of clinic visits. Here, we describe the rationale and design of a randomized, noninferiority trial designed to test the effectiveness and safety of using HIVST to support PrEP delivery in Kenya.Methods: The JiPime-JiPrEP (Kiswahili for 'Test Yourself, PrEP Yourself') study is a three-arm randomized trial taking place in Thika, Kenya. Participants (n = 495) are eligible for enrollment if they are at least 18 years old, HIV-1 seronegative, and have been taking PrEP for 1 month. Three distinct participant types will be enrolled: men (n = 165) and women (n = 165) who are in mutually disclosed HIV-1 serodiscordant relationships, and women (n = 165) who are at HIV-1 risk and not in a known serodiscordant relationship. Participants in each of these subpopulations will be 1:1:1 randomized to: 1) the standard of care, with quarterly clinic visits; 2) oral HIVST, with biannual clinic visits plus oral HIVSTs to use at the quarters between those visits; or 3) blood-based HIVST, with biannual clinic visits plus blood-based HIVSTs. All participants will complete quantitative surveys and provide blood samples for the objective measurement of PrEP adherence at baseline, 6 months, and 12 months. The primary outcomes are PrEP adherence, PrEP continuation, and HIV-1 testing, measured at 6 months and secondarily at 12 months.Discussion: The findings from this trial can help to understand how HIVST-a new HIV-1 testing technology-can support health systems in sub-Saharan Africa. Additionally, the findings can inform policy aimed at improving the efficiency of PrEP implementation and scale-up in Kenya.Trial Registration: ClinicalTrials.gov, NCT03593629 . Retrospectively registered on 20 July 2018. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF